1
|
Birkett L, Dhar S, Singh P, Mosahebi A. Botulinum Toxin A in the Management of Acne Vulgaris: Evidence and Recommendations. Aesthet Surg J 2022; 42:NP507-NP509. [PMID: 35171221 PMCID: PMC9208820 DOI: 10.1093/asj/sjac037] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Affiliation(s)
- Liam Birkett
- Corresponding Author: Dr Liam Birkett, 1106 Cassia Point, 2 Glasshouse Gardens, Stratford, London E20 1HW, UK. E-mail:
| | | | | | | |
Collapse
|
2
|
Norizadeh Tazehkand M, Yılmaz MB. Klorzoksazonun antibakteriyel etkisinin belirlenmesi. CUKUROVA MEDICAL JOURNAL 2019. [DOI: 10.17826/cumj.459036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
3
|
Romo PGB, Smith CP, Cox A, Averbeck MA, Dowling C, Beckford C, Manohar P, Duran S, Cameron AP. Non-surgical urologic management of neurogenic bladder after spinal cord injury. World J Urol 2018; 36:1555-1568. [PMID: 30051263 DOI: 10.1007/s00345-018-2419-z] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2018] [Accepted: 07/19/2018] [Indexed: 12/21/2022] Open
Abstract
PURPOSE To review the available data on non-surgical management for neurogenic bladder in patients with spinal cord injury (SCI). Before the introduction of urinary catheters and antibiotics, neurogenic bladder was one of the main culprits for death in those patients with SCI. Currently, the management of neurogenic bladder is focused in improving quality of life and preserving renal function. METHODS A literature review was performed and therapeutic management for neurogenic bladder was divided in six sections: (1) intermittent bladder catheterization; (2) indwelling catheters; (3) condom catheter drainage; (4) reflex voiding and bladder expression with Valsalva or Credé; (5) oral drug therapy of the spinal cord injured bladder; and (6) botulinum neurotoxin (BoNT). RESULTS Intermittent catheterization is recommended as the preferable method for management of neurogenic bladder in patients with SCI based on limited high-quality data. However, this may not be feasible or available to all and other alternative options include condom catheter drainage or indwelling catheters such as urethral catheters or suprapubic tube, reflex voiding, and bladder expression with Valsalva or Credé. Non-invasive medical therapies are the key to improve incontinence, urodynamic parameters, and quality of life in this population. Botulinum neurotoxin has revolutionized the management of neurogenic bladder in the last two decades decreasing the need for reconstruction or diversion. CONCLUSION The Joint SIU-ICUD (Société Internationale d'Urologie) (International Consultation on Urological Diseases) International Consultation reviewed the available presented data and provided specific conclusions and recommendations for each non-surgical urologic method to address neurogenic bladder after SCI.
Collapse
Affiliation(s)
| | | | - Ashley Cox
- Dalhousie University, Halifax, NS, Canada
| | | | | | | | | | - Sergio Duran
- National Institute of Rehabilitation, Mexico City, Mexico
| | - Anne P Cameron
- University of Michigan, Ann Arbor, MI, USA. .,Division of Neurourology and Pelvic Reconstructive Surgery, Department of Urology, The University of Michigan Medical Center, 1500 East Medical Center Drive, Taubman Center 3875, Ann Arbor, MI, 48109-5330, USA.
| |
Collapse
|
4
|
Leitner L, Sammer U, Walter M, Knüpfer SC, Schneider MP, Seifert B, Tornic J, Mehnert U, Kessler TM. Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity. Sci Rep 2016; 6:33197. [PMID: 27616488 PMCID: PMC5019002 DOI: 10.1038/srep33197] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Accepted: 08/19/2016] [Indexed: 11/16/2022] Open
Abstract
Many of the patients undergoing intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity (NDO) present with chronic bacteriuria. In these patients, antibiotic prophylaxis has been widely recommended since bacteriuria might impair treatment efficacy and cause urinary tract infections (UTI) but the evidence is limited. The aim of this study was to evaluate if an antibiotic prophylaxis is needed in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections. Between 06/2012 and 12/2014, a consecutive series of 154 patients undergoing a total of 273 treatment cycles were prospectively evaluated. Before treatment urine samples were collected, patients with no clinical signs for UTI underwent onabotulinumtoxinA injections, no antibiotic prophylaxis was given. Asymptomatic bacteriuria was found in 73% (200/273 treatments). Following treatment, UTI occurred in 5% (9/200) and 7% (5/73) of patients with and without bacteriuria, respectively. Intradetrusor onabotulinumtoxinA injections were clinically and urodynamically successful in 70% (192/273). There was no association between bacteriuria and treatment-related adverse events (odds ratio 0.64, 95% CI 0.23–1.81, p = 0.4) nor between bacteriuria and therapy failure (odds ratio 0.78, 95% CI 0.43–1.43, p = 0.4). Thus, we conclude that antibiotic prophylaxis needs to be critically reconsidered in patients undergoing intradetrusor onabotulinumtoxinA injections, especially taking into account the alarming antibiotic resistance worldwide.
Collapse
Affiliation(s)
- Lorenz Leitner
- Neuro-Urology, Spinal Cord Injury Center &Research, University of Zürich, Balgrist University Hospital, Zürich, Switzerland.,Department of Urology, University Hospital Basel, Basel, Switzerland
| | - Ulla Sammer
- Neuro-Urology, Spinal Cord Injury Center &Research, University of Zürich, Balgrist University Hospital, Zürich, Switzerland
| | - Matthias Walter
- Neuro-Urology, Spinal Cord Injury Center &Research, University of Zürich, Balgrist University Hospital, Zürich, Switzerland
| | - Stephanie C Knüpfer
- Neuro-Urology, Spinal Cord Injury Center &Research, University of Zürich, Balgrist University Hospital, Zürich, Switzerland
| | - Marc P Schneider
- Neuro-Urology, Spinal Cord Injury Center &Research, University of Zürich, Balgrist University Hospital, Zürich, Switzerland.,Brain Research Institute, University of Zürich and Department of Health Sciences and Technology, Swiss Federal Institute of Technology Zürich, Zürich, Switzerland
| | - Burkhardt Seifert
- Epidemiology, Biostatistics and Prevention Institute, Department of Biostatistics, University of Zürich, Zürich, Switzerland
| | - Jure Tornic
- Neuro-Urology, Spinal Cord Injury Center &Research, University of Zürich, Balgrist University Hospital, Zürich, Switzerland
| | - Ulrich Mehnert
- Neuro-Urology, Spinal Cord Injury Center &Research, University of Zürich, Balgrist University Hospital, Zürich, Switzerland
| | - Thomas M Kessler
- Neuro-Urology, Spinal Cord Injury Center &Research, University of Zürich, Balgrist University Hospital, Zürich, Switzerland
| |
Collapse
|
5
|
Baron M, Grise P, Cornu JN. How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage? World J Nephrol 2016; 5:195-203. [PMID: 26981445 PMCID: PMC4777792 DOI: 10.5527/wjn.v5.i2.195] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Revised: 12/30/2015] [Accepted: 01/29/2016] [Indexed: 02/06/2023] Open
Abstract
Intradetrusor injections of botulinum toxin are the cornerstone of medical treatment of neurogenic detrusor overactivity. The primary aim of this treatment is to ensure a low pressure regimen in the urinary bladder, but the mechanisms leading to long-term protection of the urinary tract remain poorly understood. In this paper, we highlight the potential benefits of intradetrusor injections of botulinum toxin regarding local effects on the bladder structures, urinary tract infections, stone disease, vesico ureteral reflux, hydronephrosis, renal function based on a comprehensive literature review.
Collapse
|
6
|
Écologie bactérienne et profils de résistance aux antibiotiques chez les patients avec hyperactivité du détrusor d’origine neurologique, traités par injections de toxine botulique intradétrusoriennes. Prog Urol 2014; 24:744-9. [DOI: 10.1016/j.purol.2014.07.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2013] [Revised: 07/04/2014] [Accepted: 07/22/2014] [Indexed: 11/18/2022]
|